Shop

The Wall Street Journal reports on Medicare's decision to reverse itself on covering a drug that keeps elderly people afflicted with an eye disease from going blind. "...When Health and Human Services Secretary Tommy Thompson announced that Medicare would begin covering the costs of treating an aggressive from of eye disease that causes blindness in the elderly, it was good news for Susan Ventresca," the Journal article begins. "Although a new drug known as Visudyne was keeping the disease at bay in her right eye, the $1,800 cost per treatment session was more than she could afford. But several days later, in a highly unusual turn-around, Medicare...said it would reconsider its decision." The Journal goes behind the scenes to discover the pressure brought to bear behind the decision, and the consequences for those affected.

This file is not available for digital download. IRE members may place an order by emailing rescntr@ire.org